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Abstract
Aims/hypothesis The aim of this study was to develop a core
outcome set (COS) for trials and other studies evaluating the
effectiveness of prepregnancy care for women with
pregestational (pre-existing) diabetes mellitus.
Methods A systematic literature review was completed
to identify all outcomes reported in prior studies in this
area. Key stakeholders then prioritised these outcomes
using a Delphi study. The list of outcomes included in
the final COS were finalised at a face-to-face consensus
meeting.
Results In total, 17 outcomes were selected and agreed on for
inclusion in the final COS. These outcomes were grouped
under three domains: measures of pregnancy preparation
(n = 9), neonatal outcomes (n = 6) and maternal outcomes
(n = 2).
Conclusions/interpretation This study identified a COS
essential for studies evaluating prepregnancy care for women
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with pregestational diabetes. It is advocated that all trials and
other non-randomised studies and audits in this area use this
COSwith the aim of improving transparency and the ability to
compare and combine future studies with greater ease.
Keywords Clinical diabetes . Healthcare delivery . Other
techniques . Pregnancy
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Introduction
Women with pre-existing diabetes during pregnancy, also
referred to as pregestational diabetes, have an increased risk
of adverse pregnancy outcomes including congenital
anomalies, stillbirth and perinatal mortality [1, 2]. It is well
established that these risks can be reduced by attendance at
prepregnancy care [3, 4]. Prepregnancy care describes the
targeted support and additional care offered to women who
are planning pregnancy [4]. It typically involves regular
review by a multidisciplinary diabetes team in a dedicated
outpatient clinic. In general, women attending prepregnancy
care undergo a full medication review, assessment and
treatment of diabetes complications as required and
optimisation of glycaemic control. However, there is not an
agreed proforma for delivery of this care and, while many
groups have reported positive benefits associated with specific
programmes, the outcomes reported are varied [3–5]. This
inconsistency raises concern for outcome selection bias,
makes meaningful comparison between studies difficult and
limits the ability to combine the findings of individual studies
into summary estimates [6]. One approach to overcome this
lack of uniformity is to develop a core outcome set (COS) or
an agreed set of outcomes. The goal is that the COS will be
collected and reported in all studies that report a specific
clinical condition [7]. It represents a minimum that should
be collected and reported, but does not restrict researchers
from adding additional outcomes at their discretion. The
development of a COS across multiple disciplines is
supported by the Core Outcome Measures in Effectiveness
Trials (COMET) initiative, which brings together interested
researchers and minimises duplication of work [7, 8]. The
Core Outcome Set – STAndards for Reporting (COS-STAR)
statement aims to standardise COS reporting for the benefit of
all users [9]. More specifically, in the field of women’s health,
the editors of over 50 journals recently endorsed the Core
Outcomes in Women’s Health (CROWN) initiative [10].
Launched in 2014, this initiative has several aims including
encouraging COS development and facilitating effective
dissemination of manuscripts.
The aim of this study was to develop a COS for trials and
other studies evaluating the effectiveness of prepregnancy
care for women with pregestational diabetes mellitus.
Methods
This study is registered in the COMET database and a detailed
study protocol was published previously [6, 11]. Ethical
approval for the study was obtained from the Galway
University Hospital ethics committee. The COSwas developed
by completing a systematic literature review to identify
all outcomes reported in prior studies in this area. Key
stakeholders then prioritised these outcomes using a Delphi
study, providing a preliminary COS. The list of outcomes
included in the COS were finalised at a face-to-face consensus
meeting.
Systematic review The protocol for the search strategy has
been published previously [6]. The following databases were
searched for relevant studies: MEDLINE, EMBASE, Web of
Science, the Cochrane Library and the Cumulative Index to
Nursing and Allied Health Literature (CINAHL).
Clinicaltrials.gov was searched for relevant ongoing trials.
We included prospective cohort studies, case–control
studies, randomised trials and systematic reviews published
in the English language that evaluated prepregnancy care for
women with diabetes. Two reviewers (F. P. Dunne and A. M.
Egan) independently assessed the titles and abstracts of
identified studies. Full texts of studies meeting the inclusion
criteria (or in the case of uncertainty regarding inclusion) were
retrieved and consensus was achieved on inclusion status. The
reviewers then extracted the following data from each study:
study design, author details, year and journal of publication,
targeted condition, intervention under investigation, each
outcome specified in methods or findings, definition and
method of collection used (if available) and time points or
periods of outcome measurement. Following review by F. P.
Dunne, A. M. Egan, D. Devane and three additional key
stakeholders known as the study advisory group (SAG),
outcomes were grouped under three domains: measures of
pregnancy preparation, neonatal outcomes and maternal
outcomes.
Delphi study Questionnaires were completed online using
SurveyMethods software (www.surveymethods.com;
accessed 21 March 2017). Participants were recruited from
within the following groups: women with diabetes,
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midwives, obstetricians, paediatricians/neonatologists, policy
makers, other service providers and researchers with an
interest in diabetes in pregnancy. We sent an email inviting
participation to the list managers in the following
organisations: International Association of the Diabetes and
Pregnancy Study Groups (IADPSG), Diabetes Ireland (DI),
Irish Endocrine Society (IES), International Federation of
Gynecology and Obstetrics (FIGO), European Board and
College of Obstetrics and Gynaecology (EBCOG), Irish
Nutrition and Dietetic Institute (INDI), Irish Institute of
Obstetricians and Gynaecologists, Saolta Healthcare Group
(Ireland), EASD and the Diabetic Pregnancy Study Group
(DPSG) of the EASD. Snowball sampling was encouraged
(i.e. participants were asked to forward the invitation to others
whom they regarded as having the required expertise).
In the round 1 survey instrument, outcomes identified
following the systematic review were presented to
participants, grouped by domain. Related outcomes were
presented alongside each other (e.g. measures of glucose
control during pregnancy). Participants were asked to rate
each one on a nine point Likert-type scale with higher values
representing increased importance for inclusion in the COS.
Participants had an opportunity to list additional outcomes for
consideration in subsequent rounds of development. Study
participants gave informed consent prior to the submission
of any answers and the following information was also
requested: name, email address, sex, stakeholder group and
country of residence. The results of round 1 were summarised
using descriptive statistics. All outcomes were carried forward
to round 2 including additional outcomes suggested by
participants in round 1. Participants who responded to round
1 were invited to participate in round 2. In round 2, they were
shown their scores from round 1 and presented with the
distribution of scores for each outcome per stakeholder group.
Participants were invited to re-score the outcomes. All
outcomes that had a median score of ≥4 for any group were
carried forward to round 3. Participants who completed
rounds 1 and 2 were invited to complete round 3. Each
participant was presented with their round 2 scores and the
distribution of scores for each outcome as per stakeholder
group. Participants were asked to re-score the outcomes.
Outcomes were classified as ‘consensus in’ (≥70% partici-
pants scoring as 7–9 and <15% scoring as 1–3), ‘consensus
out’ (≥70% scoring as 1–3 and <15% scoring as 7–9) or ‘no
consensus’ (anything else) [12].
Consensus meeting This final phase involved a face-to-face
meeting with key stakeholders representing a range of views
of service users, clinicians and researchers. The meeting was
chaired by D. Devane, who did not vote at the meeting.
Outcomes classified as ‘consensus in’ or ‘no consensus’ were
presented to the group along with the response results from
round 3 of the Delphi study. There was opportunity for open
discussion and for combining or modifying individual
outcomes. Participants were asked to vote on each listed
outcome as ‘yes’ or ‘no’ for inclusion in the final COS.
Outcomes for which ≥70% of participants voted ‘yes’ were
carried forward to a further discussion and a second, final,
vote. An outcome was included in the COS when ≥70%
participants voted ‘yes’ in this final vote. Participants used
Poll Everywhere, a downloadable application, to place their
vote anonymously (www.polleverywhere.com; accessed 21
March 2017).
Results
Systematic review A total of 1127 titles and abstracts were
identified. Following review of the title and/or abstracts, 90
full text papers were retrieved and assessed for eligibility.
A further 57 papers were excluded following full text
assessment, leaving 33 papers in the review (Fig. 1) [3–5,
13–42]. Following data extraction, 86 individual outcomes
were identified. These were grouped according to the
following domains: measures of pregnancy preparation
(n = 38), neonatal outcomes (n = 32) and maternal outcomes
(n = 16).
Delphi study The 86 outcomes extracted were presented to
the participants grouped by domain. There were 151
respondents to the round 1 instrument (74.2% female) with
representation from 24 countries and five continents. A total
of 72.2% respondents were from Ireland and the UK.
1127 potentially relevant studies were retrieved 
1037 were excluded 
following 
title/abstract review 
90 full text papers 
were retrieved and 
assessed 
57 papers were 
excluded following 
assessment 
33 papers were 
included in the 
review 
86 individual 
outcomes were 
identified 
Fig. 1 Selection of studies for systematic review
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Stakeholders were grouped into three categories. Category 1
consisted of adult endocrinologists (n = 43, 28.5%), diabetes
nurse specialists (n = 8, 5.3%) and dietitians (n = 2, 1.3%).
Category 2 consisted of midwives (n = 17, 11.3%) and
obstetricians (n = 23, 15.2%). Category 3 consisted of women
with diabetes (n = 20, 13.2%), policy makers (n = 1, 0.7%),
researchers in the area of diabetes (n = 14, 9.3%), advocates
on behalf of those with diabetes (n = 2, 1.3%) and others
(n = 21, 13.9%). Those that selected ‘other’ were from a
variety of healthcare backgrounds and included GPs,
anaesthesiologists and neonatologists. ESM Table 1 outlines
the median score for each outcome based on the response to
the round 1 instrument. An additional 27 outcomes were
suggested by round 1 respondents and included in round 2.
Round 2 participants were asked to rate 113 outcomes as
follows: measures of pregnancy preparation (n = 51), neonatal
outcomes (n = 39) and maternal outcomes (n = 23). The round
2 instrument was completed by 120 people who had
completed round 1 (78.4%). ESM Table 1 outlines the median
score for each outcome based on the responses to the round 2
instrument. All outcomes had a median score of ≥4 and,
therefore, 113 outcomes were carried forward to round 3.
The round 3 instrument was completed by 101 participants
who had completed round 2 (84.2%) and the median score for
each outcome is outlined in ESM Table 1. ESM Table 2
outlines the percentage of round 3 participants scoring each
outcome as 1–3, 4–6 and 7–9 on the nine point scale. A total
of 84 (74.3%) outcomes were classified as ‘consensus in’ and
29 (25.7%) were classified as ‘no consensus’.
Consensus meeting The consensus meeting involved 14
stakeholders, a chairperson and two administrators. The
stakeholders included two women with type 1 diabetes, five
adult endocrinologists, one diabetes nurse specialist, two
midwives (of whom, one has type 1 diabetes), two
obstetricians and two researchers in the area of diabetes and
pregnancy. ESM Table 3 outlines the percentage of
participants voting ‘yes’ for each outcome in rounds 1 and 2.
Based on the views of the group, several outcomes were
rephrased and/or combined. These are described in the ESM.
Voting took place for each outcome in the modified list of
outcomes (n = 108). Following round 1 voting, 20 outcomes
were considered for inclusion in the COS. Following further
discussion and round 2 voting, 17 outcomes were selected and
agreed on for inclusion in the final COS as presented in
Table 1.
Discussion
In this study, 17 core outcomes were identified and agreed on
for inclusion in a COS essential for studies evaluating
prepregnancy care for women with pregestational diabetes.
These outcomes were grouped into three domains that include
measures of pregnancy preparation, neonatal outcomes and
maternal outcomes. It is advocated that all trials and other
non-randomised studies and audit in this area use this COS
with the aim of improving transparency and the ability to
compare and combine future studies with greater ease.
The rationale for the development of such a COS is
convincing. A recent survey of 788 Cochrane reviews found
that 37% of prespecified outcomes were not actually reported
[43]. A 2012 systematic review and meta-analysis of
prepregnancy care for women with pregestational diabetes
noted a wide variety in outcomes reported in the included
studies [44], a finding that significantly limits interpretation
of the results. Additionally, considering a recent Cochrane
review on preconception care for diabetic women advising
the need for further high-quality studies in this area [45], it is
important that there is guidance on selecting appropriate
outcomes for evaluation. This study fills an important gap in
the literature, as there is currently no COS for prepregnancy
care for women with diabetes.
This study has several strengths. Robust consensus
methodology and guidance from the COMET initiative were
used to develop the COS [11]. A detailed study protocol was
published [6] and the COS-STAR statement was used to
ensure clarity and a high standard of reporting [9]. The
Delphi process aims to elicit and condense the opinions of
many towards consensus. It facilitates a large and international
Table 1 Final COS to be included in all studies of prepregnancy care
for women with pregestational diabetes (n = 17)
Domain Outcome
Measures of pregnancy
preparation (n = 9)
Healthcare professional review prior to
conception
Smoking status at first antenatal visit
Use of folic acid preconception
Thyroid function at first antenatal visit
Use of potentially teratogenic medications
at conception
Gestational age at first antenatal visit
BMI at first antenatal visit
BP at first antenatal visit
First trimester HbA1c
Neonatal outcomes (n = 6) Perinatal mortality
Miscarriage
Congenital malformation
Preterm birth
Large for gestational age
Small for gestational age
Maternal outcomes (n = 2) Gestational weight gain
Severe maternal hypoglycaemia in first
trimester
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participation, and it allows each participant to have an equal
voice in rating and suggesting additional outcomes for
consideration. There is a lack of consensus on optimal
consensus meeting size and representativeness is assessed on
the qualities of the expert panel rather than the numbers
[46, 47]. As outlined in our protocol, we included three service
users along with a diverse group of experienced healthcare
professionals and researchers representing a broad range of
viewpoints [6]. The opinion of the participants was that the
consensus meeting was collaborative and inclusive. Prior to
altering any outcomes from the Delphi study, significant
discussion took place with opinions invited from all
participants. The downloadable electronic application used
for anonymous voting prevented individuals feeling
pressurised to vote in a certain way.
A limitation of the systematic review is the inclusion of
studies published in the English language only, which may
have introduced a selection bias. Following the systematic
review, the determination of three domains introduced
subjectivity in terms of outcome categorisation. Several
independent reviews were taken to reduce this. The study
protocol stated that within each domain outcomes would be
listed alphabetically [6]. The intent was to avoid weighting of
outcomes caused by the order in which they were displayed.
In the actual study, related outcomes were presented alongside
each other. The SAG felt that this was more appropriate and
would encourage participants to consider overlap between
outcomes within domains during the scoring process. In
relation to the online survey, the authors acknowledge the risk
of nonresponse bias. Due to our sampling approach, we do not
have an appreciation for the numbers of potential participants
who declined to respond; however, approximately one-third
of round 1 participants did not continue to complete round 3.
In addition, while participants came from a variety of
backgrounds and countries of residence, the majority were
European and developing countries were not represented.
The potential effect of this is not easily measurable but it
may limit the generalisability of the study to less affluent areas
of the world.
The final number of outcomes included in the COSmay be
considered relatively large; however, this is related to the
nature of prepregnancy care which has potential effects
before, during and after pregnancy for two individuals, both
mother and child. The authors wish to highlight that in the
setting of future randomised controlled trials in this area, we
would not expect an inappropriately large number of primary
outcomes to be selected, but rather ensure these outcomes are
collected and reported during the study. Another potential
criticism of this study is that it does not provide outcome
definitions. It must be specified that the purpose of the COS
is to define ‘what is to be collected’ and not ‘how it is to be
collected’. In the field of diabetes and pregnancy, there exists a
previously published repository of definitions that may be
referenced as required [48]. Finally, it must be acknowledged
that many outcomes were carried forward and selected out in
the final, consensus meeting phase of the study. During this
phase, delegates were chosen to ensure representation from all
stakeholder groups and close attention was paid to outcome
scores from round 3 of the Delphi prior to excluding any
outcome from the COS.
In conclusion, comparisons between studies evaluating
prepregnancy care for women with pregestational diabetes
are difficult due to inconsistencies in the approach to
collecting and reporting data. This is the first study to define
a COS in this area. Its goal is that use of this COS will
facilitate international collaboration and allow accurate
contrasting and combining of findings. This will make it easier
to assess the effect of prepregnancy care, accurately inform
policy developers and improve evidence-based practice for
women with diabetes.
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